On the reliability of quantitative clinical magnetic resonance spectroscopy of the human brain

Schirmer, Timo; Auer, Dorothee P.

doi:10.1002/(sici)1099-1492(200002)13:1<28::aid-nbm606>3.0.co;2-l

Cited by 140 publications

(74 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In all of these studies the concentrations of the other metabolites remained constant with time to within experimental error, as would be expected. Detailed studies 3,7,8 of intra-assay and inter-assay reproducibility with LCModel are discussed below.…”

Section: Results and Discussion Validationmentioning

confidence: 99%

“…Figure 2 shows a relatively high-quality spectrum from normal human gray matter (at 2.0 T with STEAM, TE/ TM/TR = 20/30/3000 ms, 128 scans and 18 mL volume). Even at lower resolution, the reproducibilities of LCModel estimates at 2.0 T 1,4 and 1.5 T 3,8 indicate that a considerable number of metabolites can be reliably estimated. Figure 3 shows an unusually low-resolution spectrum (from abnormal human gray matter in vivo at 2.0 T with STEAM, TE/TM/TR = 20/30/3000.…”

Section: Baselinementioning

confidence: 99%

See 1 more Smart Citation

Automatic quantitation of localized in vivo¹H spectra with LCModel

2001

View full text Add to dashboard Cite

The LCModel method analyzes an in vivo spectrum as a Linear Combination of Model in vitro spectra from individual metabolite solutions. Complete model spectra, rather than individual resonances, are used in order to incorporate maximum prior information into the analysis. A nearly model-free constrained regularization method automatically accounts for the baseline and lineshape in vivo without imposing a restrictive parameterized form on them. LCModel is automatic (non-interactive) with no subjective input. Approximately maximum-likelihood estimates of the metabolite concentrations and their uncertainties (Cramér-Rao lower bounds) are obtained. LCModel analyses of spectra from users with fields from 1.5 to 9.4 T and a wide range of sequences, particularly with short TE, are used here to illustrate the capabilities and limitations of LCModel and proton MRS.

show abstract

Section: Results and Discussion Validationmentioning

confidence: 99%

Section: Baselinementioning

confidence: 99%

Automatic quantitation of localized in vivo¹H spectra with LCModel

2001

View full text Add to dashboard Cite

show abstract

“…Therefore, we cannot be completely sure about the reproducibility of our measurements. Other studies suggest that reproducibility of 1 H-MRS (Schirmer and Auer, 2000), DTI (Brockstedt et al, 1999;Cassol et al, 2004) and PWI (Henry et al, 2001) is good, although this might depend on the scanner, the scan protocol, and post-processing procedures. ROIs were drawn in the spatially normalized MNI brain template, which may have introduced additional variance due to inherent variations in mapping of individual brains to the MNI brain.…”

Section: Discussionmentioning

confidence: 99%

A Prospective Cohort Study on Sustained Effects of Low-Dose Ecstasy Use on the Brain in New Ecstasy Users

Win

Reneman

Jager

et al. 2006

Neuropsychopharmacol

View full text Add to dashboard Cite

It is debated whether ecstasy use has neurotoxic effects on the human brain and what the effects are of a low dose of ecstasy use. We prospectively studied sustained effects (42 weeks abstinence) of a low dose of ecstasy on the brain in ecstasy-naive volunteers using a combination of advanced MR techniques and self-report questionnaires on psychopathology as part of the NeXT (Netherlands XTC Toxicity) study. Outcomes of proton magnetic resonance spectroscopy ( 1 H-MRS), diffusion tensor imaging (DTI), perfusion-weighted imaging (PWI), and questionnaires on depression, impulsivity, and sensation seeking were compared in 30 subjects (12M, 21.873.1 years) in two sessions before and after first ecstasy use (1.871.3 tablets). Interval between baseline and follow-up was on average 8.176.5 months and time between last ecstasy use and follow-up was 7.774.4 weeks. Using 1 H-MRS, no significant changes were observed in metabolite concentrations of N-acetylaspartate (NAA), choline (Cho), myo-inositol (mI), and creatine (Cr), nor in ratios of NAA, Cho, and mI relative to Cr. However, ecstasy use was followed by a sustained 0.9% increase in fractional anisotropy (FA) in frontoparietal white matter, a 3.4% decrease in apparent diffusion (ADC) in the thalamus and a sustained decrease in relative regional cerebral blood volume (rrCBV) in the thalamus (À6.2%), dorsolateral frontal cortex (À4.0%), and superior parietal cortex (À3.0%) (all significant at po0.05, paired t-tests). After correction for multiple comparisons, only the rrCBV decrease in the dorsolateral frontal cortex remained significant. We also observed increased impulsivity ( + 3.7% on the Barratt Impulsiveness Scale) and decreased depression (À28.0% on the Beck Depression Inventory) in novel ecstasy users, although effect sizes were limited and clinical relevance questionable. As no indications were found for structural neuronal damage with the currently used techniques, our data do not support the concern that incidental ecstasy use leads to extensive axonal damage. However, sustained decreases in rrCBV and ADC values may indicate that even low ecstasy doses can induce prolonged vasoconstriction in some brain areas, although it is not known whether this effect is permanent. Additional studies are needed to replicate these findings.

show abstract

“…More recently, Venkatraman et al 124 compared the precision (reproducibility) and variability of singlevoxel PRESS data collected from the anterior cingulate and hippocampus at 4.0 T with reproducibility (single subject scanned multiple times) [125][126][127][128][129][130][131][132][133] and variability studies (many subjects scanned at least once) 109,115,120,128 -130,134 -144 from the literature (many different regions of the brain). The motivation for the Venkatraman study was the review of Steen et al, 145 who found an average coefficient of variation (CV, % ϭ SD/mean ϫ 100) for NAA by Steen et al 145 in the frontal lobe in healthy controls of 13.7% at 1.5 T (from 16 published studies).…”

Section: Reproducibility Of Mrs Studies Of Normal Controlsmentioning

confidence: 99%

Recent Advances in Magnetic Resonance Neurospectroscopy

Rosen

Lenkinski

2007

Neurotherapeutics

View full text Add to dashboard Cite

Summary:Over the past two decades, proton magnetic resonance spectroscopy (proton MRS) of the brain has made the transition from research tool to a clinically useful modality. In this review, we first describe the localization methods currently used in MRS studies of the brain and discuss the technical and practical factors that determine the applicability of the methods to particular clinical studies. We also describe each of the resonances detected by localized solvent-suppressed proton MRS of the brain and discuss the metabolic and biochemical information that can be derived from an analysis of their concentrations. We discuss spectral quantitation and summarize the reproducibility of both single-voxel and multivoxel methods at 1.5 and 3-4 T. We have selected three clinical neurologic applications in which there has been a consensus as to the diagnostic value of MRS and summarize the information relevant to clinical applications. Finally, we speculate about some of the potential technical developments, either in progress or in the future, that may lead to improvements in the performance of proton MRS.

show abstract

On the reliability of quantitative clinical magnetic resonance spectroscopy of the human brain

Cited by 140 publications

References 22 publications

Automatic quantitation of localized in vivo¹H spectra with LCModel

Automatic quantitation of localized in vivo¹H spectra with LCModel

A Prospective Cohort Study on Sustained Effects of Low-Dose Ecstasy Use on the Brain in New Ecstasy Users

Recent Advances in Magnetic Resonance Neurospectroscopy

Contact Info

Product

Resources

About

On the reliability of quantitative clinical magnetic resonance spectroscopy of the human brain

Cited by 140 publications

References 22 publications

Automatic quantitation of localized in vivo1H spectra with LCModel

Automatic quantitation of localized in vivo1H spectra with LCModel

A Prospective Cohort Study on Sustained Effects of Low-Dose Ecstasy Use on the Brain in New Ecstasy Users

Recent Advances in Magnetic Resonance Neurospectroscopy

Contact Info

Product

Resources

About

Automatic quantitation of localized in vivo¹H spectra with LCModel

Automatic quantitation of localized in vivo¹H spectra with LCModel